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Abstract
A total of 12 Acinetobacter baumannii isolates have been recovered 
from hospitalized patients at two hospitals in Jordan over two differ-
ent periods of time (2006 and 2008). Phenotypic and biochemical 
characterization with antibiotic susceptibility testing indicated that all 
isolates were belonging to A. baumannii. A high degree of conserva-
tion of both the 16S-23S rRNA gene intergenic spacer (ITS) length 
and the ITS sequence was observed among the isolates, and their 
identities were further confirmed by amplified ribosomal DNA gene 
restriction analysis (ARDRA). The application of ITS sequence-based 
identification and ARDRA provide promising tools for the elucidation 
of the clinical significance of genospecies identification of A. bau-
mannii.
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Introduction
Studies from different parts of the world have 
demonstrated that Acinetobacter baumannii is a 
common opportunistic nosocomial pathogen, with 
increasingly global prevalence [1]. A. baumannii has 
been found to be responsible for various infections 
including nosocomial pneumonia, blood infection, 
urinary tract infection and surgical wound infection 
especially in patients hospitalized in intensive care 
unit (ICU) [1-5]. The epidemiology and control of 
A. baumannii infections in hospitals is a complex 
issue, since this organism has a great capacity to 
survive in low-moisture environment coupled with 
its ability to develop rapidly resistance to antimi-
crobial agents posing particular risk to hospitalized 
patients [4-5]. 
A study by Shehabi and Baadran (1996) revealed 
that few types of multidrug-resistant Gram-nega-
tive bacteria (A. baumanii, Pseudomonas aerugino-
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sa and klebsiella pneumoniae) were commonly as-
sociated with Jordanian ICU patients during 1993 
[6]. Since then there was increased incidence of 
A.baumannii infections and colonization in Jorda-
nian hospitals [5,7]. In addition, clinical laborato-
ries in Jordan, as other clinical laboratories in other 
parts of the world, depend mainly upon traditional 
phenotypic identification methods that relay on 
biochemical pathways and carbon source utiliza-
tion [5-7]. Investigators over the years have tried a 
variety of laboratory improvement tests for identi-
fication A.baumannii through appling phenotypic 
and genotypic techniques [8]. Of such efforts was 
the use of gas chromatographic analysis [9]. Mi-
crolog system, comprising a microtiter plate that 
tests for the ability of a microorganism to utilize 
different carbon sources [10], VITEK-2 ID-GNB card 
(bioMérieux, Hazelwood, MO), and Sherlock mi-
crobial identification system which is a fully auto-
mated gas chromatographic analytical system that 
identifies bacteria based on their unique fatty acid 
profiles [11]. A phenotypic identification of Acine-
tobacter to the species level was always considered 
presumptive, and not so accurate since it is useful 
only for rapid diagnosis of infections [12,13] .
Taxonomy of the genus Acinetobacter has re-
vealed 23 validly named species (http://www.bac-
terio.cict.fr/) and a number of DNA-DNA hybridiza-
tion groups (genomic species) with provisional des-
ignations [14]. However, the identification of Aci-
netobacter at species level is still erratic and quite 
variable that hindered progress understanding the 
pathogenic role of Acinetobacter [15]. Thus, pre-
cise identification of Acinetobacter species would 
be significant in epidemiology, and infection con-
trol policies [16]. Since 1986, the taxonomy of the 
genus Acinetobacter was revised, molecular meth-
ods provided the necessary tools to identify Aci-
netobacter at the species level. Detailed studies of 
the epidemiology of the different members of this 
genus became possible using genotyping methods 
[17]. Molecular methods that have been developed 
and validated for identification of Acinetobacters 
include amplified 16S rRNA gene restriction analy-
sis (ARDRA) [18], high-resolution fingerprint analy-
sis by amplified fragment length polymorphism 
(AFLP) [19], ribotyping [20], tRNA spacer finger-
printing [21], restriction analysis of the 16S-23S 
rRNA intergenic spacer sequences [22], sequence 
analysis of the 16S-23S rRNA gene spacer region 
[12], and sequencing of the rpoB (RNA polymerase 
β-subunit) gene and its flanking spacers [23]. Cur-
rently, ARDRA and AFLP are the most widely used 
validated reference methods for species identifica-
tion of Acinetobacters [18,19]
The tremendous increase in sequencing, lead 
to partial or nearly complete sequence analysis of 
the 16S rRNA gene for Acinetobacter classification 
[24,25]. In addition, the 16S and 23S rRNA genes 
intergenic spacer (ITS) has been suggested to be 
a good candidate for bacterial species identifica-
tion [26], since these regions have degrees of low 
intraspecies variation and high degrees of interspe-
cies divergence [27,28]. Therefore, in the present 
study we have applied 16S-23S rRNA gene inter-
genic spacer (ITS) sequencing technique to analyze 
the genotyping of clinical isolates of A.baumannii 
that were collected from two different hospitals in 
Jordan, and to correlate their genotypes with phe-
notypic characters .
Materials and Methods
Bacterial isolates
A total of 12 isolates of A. baumannii were re-
covered from 12 clinical samples and included in 
this study. Seven isolates were recovered from ICU 
patients of the King Hussein Cancer Center (KHCC) 
in 2006. The rest 5 isolates were recovered from ICU 
patients of The Jordan University Hospital in 2008. 
The clinical samples were isolated from 12 patients 
with different types of infections at two different 
periods of time. Pure clinical isolates, identified as 
A. baumannii in the microbiology laboratory of the 
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2 hospitals were supplied for conducting this re-
search. 
The isolates were subjected to repeat pheno-
typic identification using a simplified scheme for 
Acinetobacter spp [29]. In addition to colony mor-
phology, Gram staining reaction and microscopic 
characterization, the scheme included growth at 
37oC, 41oC, and 44oC, glucose oxidation, gelatin 
hydrolysis and Triple sugar iron (TSI) test [30]. Bio-
chemical reactions using API 20 NE system (bioMé-
rieuxVitek, Marcy l’Etoile, France) were also used . 
Standard control strains of Pseudomonas 
aeuroginosa (ATCC 27853) and Escherichia coli 
(ATCC 25922 strains) were used simultaneously 
with tested clinical isolates. These controls were 
used for the purposes of justifying results obtained 
in several tests including antibiotic susceptibility 
testing.
Antimicrobial susceptibility testing
The disk diffusion method on Mueller–Hinton 
agar was employed to evaluate susceptibility to 19 
antimicrobial discs. The antibiotic discs used were 
purchased from HiMedia, India, contain the fol-
lowing: Gentamycin (G) (10 µg /disc), ciprofloxa-
cin (Cf5) (5 µg /disc), levofloxacin (Le5) (5 µg /disc), 
cefuroxim (Cxm30) (30 µg/disc), pipracillin (Prl100) 
(100 µg/disc), cotrimoxazole (Smx25) (25 µg/disc), 
cefotaxime (Ctx30) (30 µg/disc), tazobactams 
(Tpz110) (110 µg/disc), colistin (Ct10) (10 µg/disc), 
ampicillin (Am10) (10 µg/disc), tetracyclin (Te30) (30 
µg/disc), cefoxitin (Fox30) (30 µg/disc), tobramycin 
(Tb10) (10 µg/disc), cefazolin (Cz30) (30 µg/disc), 
cefaclore (Cec30) (30 µg/disc), ceftazidime (Ca30) 
(30 µg/disc), moxycillin (Am30) (30 µg/disc), ofloxa-
cin (Of5) (5 µg/disc) and imipenem (Ipm10) (10 µg/
disc). Zones of inhibition were read and compared 
with the values of susceptibility interpretive break-
points issued by the National Committee for Clini-
cal Laboratory Standards (NCCLS, 2013) to deter-
mine the degree of susceptibility to each antibiotic 
tested on each isolate test [31].
Molecular manipulation
DNA preparation
A twelve DNA extract of A. baumannii isolates 
were prepared with small scale chromosome ex-
traction using Wizard Genomic DNA purification 
kit (Promega, USA) in accordance with the manu-
facturer’s instructions.
Amplification of ITS
The bacterium-specific universal primers 
1512F5`GTCGTAACAAGGTAGCCGTA3` and 6R 
5`GGGTTYCCCCRTTCRGAAAT3` where Y is C or T 
and R is A or G [32] were used to amplify a DNA frag-
ment using Gene Amp PCR system 9700 (Applied Bi-
osystems). The DNA fragment encompassed a small 
fragment of the 16S rRNA gene region, the ITS, and 
a small fragment of the 23S rRNA gene region. The 
5′ end of primer 1512F is located at position 1493 of 
the 16S rRNA gene, and the 5′ end of primer 6R is 
located at position 108 downstream of the 5′ end of 
the 23S rRNA gene (Escherichia coli numbering).
Using PCR reaction mixtures of a total volume of 
50µl were prepared for all samples as follow: 5µl 
of each primer, 2.5 µL of DNA template, 25 µL of 
Go Taq Green Master Mix (Promega, USA), and 2 
X, 12.5 µl of Nuclease-free water (up to 50 µl total 
volume). PCR was carried out in a with an initial 
denaturation step at 94°C for 2 minutes followed 
by 35 cycles of denaturation (94°C for 1 minute), 
annealing (62°C for 1 minute) and extension (72°C 
for 1 minute). The reaction was terminated with 
an extended elongation step (72 °C for 7 minutes). 
PCR products were purified using a Wizard SV gel 
and PCR clean-up System (Promega, USA). The am-
plified fragments obtained were electrophoretically 
separated in 2% agarose gels.
Identification of A. baumannii isolates  
by ITS sequencing 
DNA sequencing of the ITS of the twelve clinical 
isolates that were identified as A. baumannii with 
the API 20 NE system (bioMérieuxVitek) was car-
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ried out at the automated DNA sequencing facility 
using the TaqDyeDeoxiTerminator Cycle Sequenc-
ing Kit, and the sequence was analyzed in an au-
tomatic DNA sequencer in Korea (373A; Applied 
Biosystems).   During analysis of the sequences ob-
tained, the portions of the 16S and 23S rRNA gene 
regions were removed from the sequence data to 
obtain the exact ITS sequences. ITS DNA sequences 
of the isolates along with sequences of known Aci-
netobacter geno-species prototype strains retrieved 
from the GeneBank were aligned using molecu-
lar evolutionary genetic analysis programs (Mega 
5.10).
Identification of the isolates by ARDRA
The ARDRA method was carried out as described 
previously [18, 33]. Briefly, the amplified 16S rRNA 
gene was obtained by Gene Amp PCR system 9700 
(Applied Biosystems). The sequences of the primers 
were 59TGGCTCAGATTGAAC GCTGGCGGC39 
(59 end of the 16S rRNA gene) and 59TACCTTGT-
TACGA CTTCACCCCA39 (39 end of the 16S rRNA 
gene). Amplification was performed under the fol-
lowing conditions: initial denaturation step for 6 
min at 94°C followed by 35 cycles of denaturation 
(94°C for 45 s), annealing (60°C for 45 s), and ex-
tension (72°C for 1 min).The reaction was termi-
nated with an extended elongation step (72°C for 
7 min). Separate aliquots were digested with four 
restriction endonucleases CfoI, AluI, RsaI and MspI 
(Promega, USA). The fragments obtained by diges-
tion with each enzyme were electrophoretically 
separated in 2.5% agarose gels. Species identifi-
cation was done by comparing the profiles con-
sisting of the combination of restriction patterns 
generated with the different enzymes to those of 
a library of profiles of strains of described named 
and unnamed species [18,33] (http://allserv.rug.
ac.be/~mvaneech/ARDRA/Acinetobacter.html).
Results
Bacterial isolates
The biocharacteristics of the 12 clinical isolates 
are shown in Table 1. Re-identification of the 12 
clinical isolates using presumptive method for phe-
notypic characterization of Acinetobacter spp by 
API 20 NE system showed that all isolates belonged 
to A. baumannii  with confidence levels >90%. 
Antibiotic susceptibility testing 
A. baumannii isolates revealed 100% resistance 
to the following investigated antibiotics ( Genta-
mycin, cefuroxim, cotrimoxazole, cefotaxime, tazo-
bactams, ampicillin, tetracyclin, cefoxitin, cefaclore, 
ceftazidime, amoxycillin, cefazolin and pipracillin, 
cirofloxacin, tobramycin, oflacacin, and levofloxa-
cin, while all these were susceptible to colistin and 
imipenem.
Amplification of ITS fragments
The ITS fragments of 12 A. baumannii (genomic) 
species were amplified by PCR with primers 1512F 
and 6R. A single amplification product indicated 
a single amplicon of very constant length was ob-
served for all isolates, and all the ITS fragments were 
607bp which referred to A. baumannii (Figure 1). 
These results confirm the close similarity between all 
12 strains obtained from two different hospitals. 
Identification of clinical A. baumannii by 
ITS DNA gene sequencing
The twelve sequencing analysis revealed that the 
5′ end of the ITS sequences were ACGAAAGATT, 
whereas the 3′ end sequence were GGGGTTGTAT 
which confirmed the identification of A. bauman-
nii. The BLAST program in National Center for Bio-
technology Information was used to align the 16S-
23S rRNA intergenic spacer sequence of the new 
isolates with previously published sequences in the 
public database. ITS sequence analysis showed that 
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there was a strong similarity (86-88%) between the 
isolates and representative strains of the genus Aci-
netobacter in gene bank using the blast tool.
Identification of clinical isolates by ARDRA
The 16S rRNA gene (16S rDNA) was enzymati-
cally amplified for all the 12 isolates belonging to 
the A. baumannii, and the amplicon was restricted 
independently with the enzymes CfoI,  AluI,  RsaI 
and  MspI. Restriction patterns were analyzed by 
2.5% agarose gel electrophoresis which represents 
digestion pattern for 3 isolates, giving an overview 
of all of the patterns observed and all 12 isolates 
showed identical patterns for all restriction en-
zymes’ digest (Figure 2). The pattern interpreta-
tion deduced that the 12 isolates are Acinetobac-
ter baumannii using band analysis library at (http://
allserv.rug.ac.be/mvaneech/ARDRA/Acinetobacter.
html).
Discussion 
This study describes and compares the molecu-
lar relationships and antibiograms of A. baumannii 
Table1.  Phenotypic Characteristics and Antibiogram of the twelve clinical isolates of Acinetobacter 
baumannii
Patients’
Features
Sample No.
1 2 3 4 5 6 7 8 9 10 11 12
Gender/age F/51 F/70 M/62 M/42 M/47 F/35 F/35 F/78 F/14 F/< 1 M/58 M/34
Sample 
source
wound wound sputum sputum wound wound wound blood wound CSF wound blood
Phenotypic
Characteristics
Gram 
staining
Gram-negative coccobaccilli
Growth at
37ºC, 42oC, 
44 ºC
Heavy growth after 24 hour of incubation at 37oC, 42o C and 44 ºC
Catalase All isolates were catalase +
Oxidase All isolates were oxidase -
TSI Alkaline/ Alkaline
Glucose 
oxidation*
All isolates were Glucose oxidizers
Gelatin 
hydrolysis
All isolates liquefied gelatin
API 20NE “Excellent” identification for Acinetobacter baumannii with 94.8%.
Antibiogram
R
Gentamycin, Cefuroxim, Cotrimoxazole, Cefotaxime, Tazobactams, Ampicillin, Tetracyclin, Cefoxitin, Cefaclore, 
Ceftazidime, Amoxycillin, Cefazolin, Pipracillin, Cirofloxacin, Tobramycin, Oflacacin, Levofloxacin
S Colistin , Imipenem
*Acinetobacter isolates were tested for their abilities to oxidize glucose in Hugh and Leifson’s medium
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isolates from patients hospitalized in two intensive 
care units of 2 major hospitals in Amman, Jordan. 
The phenotypic characterization results indicated 
that all isolates were belonging to A. bauman-
nii. This preliminary result showed apparently that 
these A. baumannii isolates might be belonged to 
same clone. While genus-level characterization is 
usually sufficient for clinical diagnostic purposes, 
but it is not enough to prove the common source 
of isolates or their true genomic relationship. In 
addition, phenotypic methods are not enough to 
track transmission of isolates in hospital or help to 
understand the mechanisms of Acinetobacter in-
fections. The original sources of the infecting or-
ganisms, their clone similarity, and geographical 
spread are considered an important requirements 
for the development of appropriate infection con-
trol measures. 
Therefore, 16S-23S rRNA gene intergenic spacer 
(ITS) region as a genotypic method was performed 
for the genomic identification of these isolates. The 
results of this study demonstrated a high degree of 
conservation of both the ITS length and the ITS se-
quence of the twelve isolates which are a common 
feature in all species of Acinetobacter spp [12]. Re-
striction analysis of the amplified 16S rRNA gene 
(16S rDNA) was performed for more specific dif-
ferentiation. It was observed that multiple ARDRA 
profiles may occur among different strains of the 
same species [12]. However, the conserved restric-
tion enzyme analysis revealed that the 12 clinical 
isolates belonged to the same genomic group of 
Acinetobacter baumannii complex. 
The application of ARDRA for the identification of 
Acinetobacter species has several advantages over 
phenotypic identification. ARDRA considered rapid 
and reliable and universally applicable method for 
identification of most of the Acinetobacter genom-
ic species, thus contribute to better understanding 
of the clinical importance and epidemiology of this 
organism [17]. Summation of all phenotypic, an-
tibiogram, and genotyping results suggested that 
there might be a common origin of infection in 
both JUH and KHCC. This study demonstrated the 
same genotype causing infection /colonization at 
the two major hospitals in Amman. The potential 
Figure 1. Amplification of Acinetobacter baumannii with primers 
1512F and 6R and separation of the PCR products by 2% agarose 
gel electrophoresis. Lanes: M, 100-bp DNA ladder.
Figure 2. Restriction patterns of the amplification products obtained 
from 3 isolates amplicon of Acinetobacter baumannii. A total of 8 
ml of the postamplification reaction mixture was digested with 1. 
RsaI, 2. CfoI, 3. AluI, 4. MspI and run in a 2.5% agarose gel. Lane 
designations indicate restriction, patterns. Lane M, 100-bpair ladder 
molecular weight marker.
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sources of infection might be a common environ-
mental reservoir that spread the organism such as 
water supply, ventilator, hospital staff, intravenous 
lines or monitoring devices, surgical drains or in-
dwelling urinary catheters. To investigate the po-
tential source of Acinetobacter nosocomial infec-
tion in hospital, samples should be taken from all 
those possible sources and patients for investing 
the genotypes of isolates by other advance genetic 
methods. An important drawback of this study is a 
lack of any tracing information for the movement 
of patients within and outside the hospital and no 
tracing information on visitors to the infected pa-
tients. However, a recent study carried at the JUH , 
found that A. baumannii isolates from hospital en-
vironmental and patients’ respiratory tract sources 
have a common biological characteristics including 
much similar multidrug resistance patterns [5]. 
In conclusion, this study suggests that all 12 A. 
baumannii isolates have similar phenotypic and 
genotypic characteristics, although A. baumannii 
complex might be phenotypically homogeneous 
but genotypically heterogeneous. 
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